Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Add-on humanized antidisialoganglioside mAb improves outcomes in paediatric neuroblastoma

09 Dec 2019

Using a humanized antidisialoganglioside mAb (hu14.18K322A) in combination with induction chemotherapy appears to yield favourable outcomes in children with high-risk neuroblastoma, including induction of an early response, improvement of Curie scores (CSs) and a 2-year event-free survival (EFS), according to the results of a phase II trial.

A total of 42 patients received hu14.18K322A, which was coadministered with six courses of induction chemotherapy and followed with granulocyte–macrophage colony-stimulating factor (GM-CSF) and low-dose interleukin-2 (IL2). A busulfan/melphalan preparative regimen was used during consolidation therapy. An additional course of hu14.18K322A was given with parent-derived natural killer cells, when available, during consolidation. Hu14.18K322A, granulocyte-macrophage colony stimulating factor, IL2 and isotretinoin were then administered.

Results were favourable for the primary outcomes. Partial responses (PR) or better after the first two chemoimmunotherapy courses were documented in 32 patients (76.2 percent, 95 percent confidence interval [CI], 60.6–88.0). Furthermore, most patients achieved 2-year EFS (85.7 percent, 95 percent CI, 70.9–93.3).

The primary tumour volume decreased by a median of 76 percent (range, –100 percent to 5 percent). Thirty-one of 35 patients with stage IV disease who completed induction had CSs of 2. None of the patients experienced progression during induction.

Researchers believe that the current findings, if validated in a larger study, may change the standard of care for children with high-risk neuroblastoma.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.